Navigation Links
Ampyra is First Symptom Management Drug Developed Specifically to Treat MS, the First Oral MS Therapy Approved for MS, and the First New FDA Approved Therapy to Come Through the MS Pipeline Since 2004
Date:1/23/2010

FDA Approves Fampridine SR, Now Called Ampyra, to Improve Walking for People With All Types of Multiple Sclerosis

NEW YORK, Jan. 22 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration has approved the marketing of Ampyra™ (dalfampridine, formerly known as fampridine SR, from Acorda Therapeutics) for its ability to improve walking speed in people with any type of multiple sclerosis.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090302/DC77093LOGO)

Ampyra is the first therapy specifically approved to treat a symptom of MS, and as an oral drug it represents a big step forward for many people who may benefit from its use.  Ampyra is also the first new FDA approved therapy for MS since 2004.   http://www.nationalmssociety.org/news/news-detail/index.aspx?nid=2586

"The FDA's approval of Ampyra is wonderful news for many people with MS who experience problems with walking," said John R. Richert, MD, Executive Vice President for Research & Clinical Programs at the National MS Society. "This brings a welcome symptomatic therapy that may restore some function and make a real difference in quality of life for a large number of people with different types of MS."

Further study and clinical practice may help determine the extent to which the drug may imp
'/>"/>

SOURCE National Multiple Sclerosis Society
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. First Coast Oncology Deploying Both Naviscan(TM) PEM and AccuBoost(TM) Assisted Therapy to Optimize Breast Cancer Treatment
2. New Life Agency, Inc. Joins Forces With The Diamond Institute and Walgreens Specialty Pharmacy to Introduce the Nations First In Vitro Fertilization Insurance Program
3. First ShelterBoxes Arrive in Port au Prince - Pictures and Footage
4. WorldHeart Announces First U.S. Implant of Levacor(TM) VAD Implant at INTEGRIS in Oklahoma City
5. Span-America Announces First Quarter Conference Call On The Internet
6. Elbit Imaging Announces InSightecs First Non-Invasive Technology for Treatment of Uterine Fibroids Awarded MHLW Approval in Japan
7. JDRF Forms Partnership With Animas to Develop First-Generation Automated System for Managing Type 1 Diabetes
8. First Non-Invasive Technology for Treatment of Uterine Fibroids Awarded MHLW Approval in Japan
9. BD Announces Live Webcast of First Fiscal Quarter Earnings Conference Call
10. Rochester Medical Announces First Quarter 2010 Earnings Conference Call Tuesday, January 26, 2010
11. CVS Caremarks MinuteClinic Becomes First Retail Clinic Provider to Achieve Consecutive Accreditation Awards From The Joint Commission
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... , July 31, 2015 Egalet ... integrated specialty pharmaceutical company focused on developing, manufacturing ... closing of its previously announced underwritten public offering ... a public offering price of $11.25 per share. ... included 1,000,000 shares issued upon the exercise in ...
(Date:7/31/2015)... Calif. , July 31, 2015  Xencor, Inc. ... engineered monoclonal antibodies for the treatment of autoimmune diseases, ... appointment of Yujiro S. Hata to its ... experience in business and corporate development is a tremendous ... Ph.D., president and chief executive officer of Xencor. "Xencor ...
(Date:7/30/2015)... IRVINE, Calif. , July 30, 2015 Edwards ... the science of heart valves and hemodynamic monitoring, today announced ... company,s Board of Directors. "Bob is an ardent ... been a true privilege to have him on Edwards, board ... A. Mussallem , Edwards, chairman and CEO.  "Bob has provided ...
Breaking Medicine Technology:Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 2Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 3Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 4Xencor Appoints Yujiro S. Hata to Board of Directors 2Xencor Appoints Yujiro S. Hata to Board of Directors 3
(Date:8/2/2015)... ... August 02, 2015 , ... ... muscles and connective tissues of a woman’s pelvic organs (uterus, bladder, and ... straining, heavy lifting, obesity, constipation, multiple vaginal deliveries, genetics, smoking, and the ...
(Date:8/1/2015)... ... 2015 , ... AlignLife Office Coordinator Heather Pugh earned the position ... patients at this natural health care center in Winamac. , "Oftentimes patients are in ... role is vital to our approach because we want to focus on the patient ...
(Date:8/1/2015)... ... 2015 , ... Western University of Health Sciences’ newest class ... growing percentage of U.S. physicians, and reflects the diversity of the communities where ... message delivered by John W. Becher, DO, president of the American Osteopathic Association, ...
(Date:8/1/2015)... (PRWEB) , ... August 01, 2015 , ... The condition ... among both men and women often causing pain and discomfort. Those who spend a ... circulatory problem, and Northeast Houston Vein Center is doing what it can to create ...
(Date:8/1/2015)... ... August 01, 2015 , ... Tina Wilcoxson, owner of Freeport ... was given that honor by the National Retail Federation, the largest retail trade association ... one of three Maine business owners to be named as such. According to the ...
Breaking Medicine News(10 mins):Health News:Minimally Invasive and Robotic Treatment for Pelvic Organ Prolapse Now Available from the Specialists at Women’s Excellence in Bladder Control 2Health News:New Patient Advocate Enhances Natural Health Care 2Health News:COMP-Northwest Welcomes Class of 2019 2Health News:COMP-Northwest Welcomes Class of 2019 3Health News:COMP-Northwest Welcomes Class of 2019 4Health News:COMP-Northwest Welcomes Class of 2019 5Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 2Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 3Health News:Local Retail Advocate Wins National Recognition 2
... , , Hospitals, Physicians ... , PRINCETON, N.J., Aug. 18 Twelve New Jersey ... government to test an innovative new incentive method that aims to ... The three-year trial program could serve as a basis ...
... Benefits for fighting norovirus include cost, speed, report shows ... developed a vaccine for the common viral infection norovirus ... new vaccine was "manufactured" in a tobacco plant using ... the door to faster, more inexpensive ways to bring ...
... , AUSTIN, Texas, Aug. 18 PetRel ... door-to-door pet trans p ortation services , has ... e tMD , to provide free pet travel and pet health ... will allow guests of PetMD to access PetRelocat i ...
... , ARLINGTON, Va., Aug. 18 ... Congress will add billions of dollars of un-reimbursed cost to ... patients," says K.C. McAlpin, executive director of ProEnglish, a national ... government in the United States. , , ...
... , , ... milestones achieved and immediate plans to move forward as a well ... the treatment of diabetes mellitus. Exsulin,s focus is on development of ... suffering from type 1 (T1DM) and type 2 diabetes (T2DM). ...
... , , JACKSONVILLE, Fla., ... network, today announced its partnership with Blue Cross and Blue ... and reduce the cost of care administration for Minnesotans. Blue ... the secure exchange of administrative health information between Minnesota physicians, ...
Cached Medicine News:Health News:Medicare Picks N.J. to Test Innovative Incentive System 2Health News:Medicare Picks N.J. to Test Innovative Incentive System 3Health News:Medicare Picks N.J. to Test Innovative Incentive System 4Health News:'Cruise Ship Virus' Vaccine Stems From Tobacco 2Health News:PetRelocation.com and PetMD.com Launch Co-Branded Pet Travel and Pet Health Resources 2Health News:PetRelocation.com and PetMD.com Launch Co-Branded Pet Travel and Pet Health Resources 3Health News:Exsulin Corporation Announces Publication of Phase 2 Trial Results for Novel Islet Regeneration Treatment in Type 1 & Type 2 Diabetes 2Health News:Exsulin Corporation Announces Publication of Phase 2 Trial Results for Novel Islet Regeneration Treatment in Type 1 & Type 2 Diabetes 3Health News:Exsulin Corporation Announces Publication of Phase 2 Trial Results for Novel Islet Regeneration Treatment in Type 1 & Type 2 Diabetes 4Health News:Availity Teams with Blue Cross and Blue Shield of Minnesota to Improve Health Care Efficiencies 2Health News:Availity Teams with Blue Cross and Blue Shield of Minnesota to Improve Health Care Efficiencies 3
... CO-Oximeter Control (Bayer 800 Series) is ... monitoring the performance of blood gas, ... 270 and 800 series) instrumentation. This ... Bayer 800 Rapidlab Series instruments in ...
Liquichek Blood Gas Plus CO-Oximeter Control (IL Synthesis Series) is a combination control for use in monitoring the performance of blood gas, ion-selective electrode, biosensor and CO-Oximetry anal...
Liquichek Blood Gas Plus E Control is an aqueous product used to monitor the measurement of pH, pCO2, pO2 and electrolytes. Available in four levels....
Liquichek CK/LD Isoenzyme Control features analytes used in cardiac profile testing and protein electrophoresis. Assayed for most methods including instruments, immunoinhibition kits and electrophore...
Medicine Products: